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ABSTRACT
Tobetterdecipherthefunctionalimpactofalternative
splicing, we classified alternative splicing events in
10818 pairs of human and mouse genes based on
conservation at genome and transcript levels.
Expression levels of conserved alternative splices
in human and mouse expressed sequence tag data-
bases show strong correlation, indicating that altern-
ative splicing is similarly regulated in both species.
A total of 43% (8921) of mouse alternative splices
could be found in the human genome but not in
human transcripts. Five of eleven tested mouse pre-
dictions were observed in human tissues, demon-
strating that mouse transcripts provide a valuable
resource for identifying alternative splicing events
in human genes. Combining gene-specific measures
of conserved and diverged alternative splicing with
both gene classification based on Gene Ontology
(GO) and microarray-determined gene expression in
52 diverse human tissues and cell lines, we found
conserved alternative splicing most enriched in
brain-expressedsignalingpathways.Divergedaltern-
ative splicing is more prevalent in testis and cancer-
ous cell line up-regulated processes, including
protein biosynthesis, responses to stress and
responses to endogenous stimuli. Using conserva-
tion as a surrogate for functional significance, these
results suggest that alternative splicing plays an
important role in enhancing the functional capacity
of central nervous systems, while non-functional
splicing more frequently occurs in testis and cell
lines, possibly as a result of cellular stress and
rapid proliferation.
INTRODUCTION
Alternative splicing of pre-mRNA is a regulatory mechanism
that plays important roles in human physiology and disease
(1–3) and is a major contributor to the functional complexity
of the human genome (4). Microarray and large-scale com-
putational analysis of expressed sequence tag (EST)/cDNA
sequences have shown that alternative splicing affects at
least 50% of human and mouse genes (5–7). A number of
bioinformatics analyses have been performed to elucidate
the functional impact of alternative splicing by identifying
the enrichment of alternative splicing events in certain classes
of genes or by classifying the functional regions affected (8,9)
and, while providing valuable insights, the conclusions are not
entirely consistent [see Lareau et al. (10)]. Recent evidence
emerging from comparative genomics studies indicates that
the majority of alternatively spliced cassette exons are not
evolutionarily conserved, may result from aberrant splicing
and likely do not create functional proteins. Conversely, con-
served alternative exons more frequently create transcripts
capable of producing functional proteins as they frequently
occur outside protein domains and frequently preserve the
protein reading frame (11–14).
Hence, classifying alternative splicing forms based on
evolutionary conservation helps delineate the functionality
of alternative splice forms. Previous cross-species splicing
studies have largely focused on identifying characteristics
to predict individual exons as alternative and conserved
(11–14). In this study, we examine not only cassette exons
but also additional types of alternative splicing events in
10818 pairs of human and mouse genes. We use mouse
and human genomic and transcript sequences to classify
alternative splices into one of the three classes: conserved,
novel and diverged. Our experimental validation of novel
alternative splicing events in human genes predicted from
mouse transcripts suggests that the extent of conserved altern-
ative splicing is greater than previously estimated. Combining
*To whom correspondence should be addressed. Tel: +1 206 802 6337; Fax: +1 206 802 6411; Email: John_castle@merck.com
  The Author 2005. Published by Oxford University Press. All rights reserved.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access
version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press
areattributedastheoriginalplaceofpublicationwiththecorrectcitationdetailsgiven;ifanarticleissubsequentlyreproducedordisseminatednotinitsentiretybut
only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org
Nucleic Acids Research, 2005, Vol. 33, No. 17 5659–5666
doi:10.1093/nar/gki834gene expression and functional annotation, we identiﬁed
important distinctions between evolutionarily conserved and
diverged alternative splicing events.
MATERIALS AND METHODS
Delineating alternative splice patterns
A splice, or a junction, is a unique pair of adjacent splice sites
identiﬁed through genomic transcript alignment. As previ-
ously described (15), we used mouse and human transcripts
and genomes to identify alternative splices in human and
mouse genes. Genomic contig sequences and the LocusLink
database were downloaded from NCBI as of April, 2004 (16)
and transcript sequences were taken from UniGene releases
Hs.168 and Mm.135 (16). Orthologous gene pairing required
reciprocal best matches in the Homologene database (17). For
each gene, genomic sequence with ﬂanking 10 kb extensions
was extracted based on LocusLink coordinate annotation.
Exon and splice coordinates were identiﬁed by aligning tran-
script sequences to the genome of the same species using Sim4
(18). A program called TAP was used to identify consensus
splice patterns by clustering genomic alignments (19). Cross-
species genomic alignments were generated using
EST_GENOME (20), enabling mapping of nucleotide splice
patterns between human and mouse (21).
Classification of splices
Based on a comparison of the resulting nucleotide alignment
patterns, all splices were classiﬁed as ‘conserved’, reliably
mapped in both genomes and identiﬁed in transcripts from
both species, ‘diverged’, no matching splice junction can be
found within 10 bases in the transcript sequence based on the
cross-species alignment or ‘novel’, mapped in both genomes
but identiﬁed in transcripts of only one species. Additionally,
ifthelocation ofanexon–exonboundarywithinatranscript,as
deﬁned by genomic alignment, differs between human and
mousegenomicalignments, thesplice isclassiﬁedasdiverged.
In Figure 1, splices A and B are mapped to splices a and bfrom
the cross-species alignment. A is conserved as its counterpart,
splice a, is found in mouse transcripts whereas B is novel as
splice b is not found in mouse transcripts but is found in the
mouse genome. Splices C and D are diverged because exon 4
has no homologous match in the mouse genome and therefore
no matching splices.
For each splice, the occurrence frequency in transcripts,
relative to mutually exclusive splices, measures the relative
abundance of the underlying splice form, to the extent that
EST/cDNA sequencing constitutes an unbiased sampling of
the transcriptome (22). We deﬁne ‘major’ splices as those
observed more frequently than mutually exclusive splices or
those not having any mutually exclusive splice patterns
whereas ‘minor’ splices are those observed less frequently.
We deﬁne ‘alternative splices’ as minor splices from non-
RefSeq transcripts and ‘reference splices’ as major splices
from RefSeq transcripts. A total of 1268 gene pairs for
which over 40% of the reference exons could not be reliably
mapped between species were excluded.
Z-score
The binomial Z-score, also known as Z-ratio, measures the
difference, in units of standard deviation, between the
observed frequency and the expected frequency of an event
based on binomial probability distribution. The Z-score
approximating the expression level of a splice using transcript
occurrences is:
Z ¼
k=n ðÞ   f ±0 :5=n ðÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
f · 1 f ðÞ ½  =n
p ‚ 1
where k is the observed number of sequences containing a
splice, n is the total number of overlapping sequences, and
f is the expectation of 50% (22).
Quantifying gene-specific alternative splicing
To quantify the amount of alternative splicing for a gene, we
counted the number of distinct splices found in the associated
transcripts, yielding a ‘splice count’ for each gene. Gene-to-
gene comparisons are confounded by factors such as differ-
ences in transcript coverage and in the number of exons. We
found that the level of alternative splicing can be approxim-
ated by the natural logarithm of spliced transcript coverage
(Supplementary Figure S1). Thus, to mitigate differences in
Figure 1. Classificationofsplicepatternsbasedonconservation.Shownaboveisahumantranscriptalignedto humanandmousegenomicsequences,definingtwo
setsofexons(shaded)andsplices(dashed).Eachsplicecorrespondstoasplicejunctioninthetranscriptsequenceandcanbematchedtoacross-speciesspliceifthe
positions of two splice junctions on the transcript coincide.
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the log of the transcript coverage, resulting in a normalized
overall splice score and normalized conserved, diverged, and
novel splice scores for each gene.
Expression and functional classification
We classiﬁed tissues and gene functional categories based on
conserved and diverged alternative splicing. For each Gene
Ontology (GO) Biological Process in the ‘generic slim’ divi-
sion, the rate of normalized conserved alternative splicing of
the underlying gene sets was used to generate a t-score. For
each gene set the t-score is calculated as:
t ¼
k m
s=
ﬃﬃﬃ
n
p ‚ 2
where s is the deviation in units of standard error, k is the
observed sample mean, m is the global population mean, and n
isthe gene-setsize.Associations betweenindividualgenes and
GO terms were derived from NCBI’s LocusLink.
Microarray measurements of 10000 human genes across
52 human tissues (7) were used to determine gene expression.
In this experiment, each gene was monitored by multiple
junction-speciﬁc probes and we obtained the expression
level for the entire gene by taking the mean intensity. Logar-
ithm based 10 ratios for each gene in each tissue were deter-
mined by comparison with the average intensity value across
all 52 tissues, for the gene. A gene is classiﬁed as over-
expressed in a tissue if it is expressed above noise levels
and the log10 ratio is >2.
Tissue origin classification of alternative splices
Tissue origins of human ESTs, and thus individual splices,
were identiﬁed based on gene expression vocabulary (eVOC)
annotations of cDNA library sources, as provided by UniGene
Library Browser (17) and eVOC (23). Tissue names were
taken from level three of the anatomical system hierarchy
of eVOC except for four large and heterogeneous categories,
‘liver and biliary system’, ‘genital’, ‘central nervous system’
and ‘peripheral nervous system’, which were subdivided. This
resulted in a total of 30 normal tissue types after excluding
diseased and fetal tissues and tissues with very few ESTs. For
each splice, we count the transcript sequences containing the
splice in each tissue (k), in all tissues (n), and the percentage of
all sequences in each tissue (f). The distribution bias of altern-
ative splices in each tissue is also quantiﬁed by Z-score
representing the deviation between the observed frequency
of a splice sequence count and the expected frequency,
using Equation 1.
RT–PCR validation
The Qiagen OneStep RT–PCR kit (Qiagen Catalog no.
210212) was used with gene-speciﬁc primers. The PCR com-
ponent involves35 cycles at30 Cfor94 h, 40 C for63.5 hand
50–120 C for 72 h depending on the predicted size of the
product. All products are resolved on a 2% agarose gel run
at 100 V in TAE buffer. A diverse set of 44 human mRNA
tissues and cell lines were used: adipose; adrenal gland; bone
marrow; brain, cerebellum; brain, frontal lobe; brain,
hippocampus; brain, medulla oblongata; brain, pons; brain,
putamen; brain, thalamus; colon, descending; colon tumor
tissue; fetal brain; fetal kidney; fetal liver; fetal lung; fetal
vertebra; heart; HeLa S3; ileum; jejunum; kidney; leukemia
promyelocytic (HL-60); liver; lung; lung carcinoma (A549);
lymphoma burkitt’s (Raji); melanoma (G361); osteosarcoma
(MG-63); ovary; pancreas; peripheral leukocytes; pituitary;
placenta; prostate; retina; skeletal muscle; skin; spinal cord;
stomach; testis; thymus; thyroid; uterus.
RESULTS
Genome-wide survey of alternative splices
In our dataset of 10818 genes and 140103 distinct human
splices, 64% are reference splices whereas 26% are alternative
splices (Table 1). When compared with mouse transcript and
genome sequences, the vast majority of human alternative
splices are either diverged (49%) or novel (44%). Only 7%
of alternative splices are conserved in mouse transcripts versus
85% of reference splices, corroborating previous estimates of
lower conservation of alternatively spliced exons
(11,12,24,25).
Prediction and experimental validation of novel
alternative splices
Almost 43% of mouse alternative splices (8921) can be
mapped to the human genome but are not currently found
in human transcripts. A signiﬁcant proportion of these are
likely species-speciﬁc variants (13). Nevertheless, we were
able to validate 5 of 11 predictions using RT–PCR across a
panel of 44 human tissues (Supplementary Table S1). These
predictions were randomly selected from a list of human genes
enriched for genes with therapeutic interest using the follow-
ing criteria: (i) the predicted alternative splices must have
multiple mouse transcripts as support evidence and (ii) the
predicted alternative splices are not found in human transcript
databases at the time of analysis. Although the sample size is
small, the 45% validation rate suggests that a signiﬁcant frac-
tion of conserved alternative splices identiﬁed by one species’
transcripts are currently not present in the other species’
transcripts.
We can conceptually divide all conserved alternative spli-
cing events in human and mouse genes into four categories—
those already found in both human and mouse transcripts
(transcript conserved), those found in mouse transcripts but
not found in human transcripts (mouse only), those found in
human transcripts but not found in mouse transcripts (human
Table 1. Alternative splicing statistics
Alternative splices Human Mouse
Number Genes Number Genes
Conserved 2526 (7%) 1635 2526 (12%) 1635
Diverged 17743 (49%) 6239 9451 (45%) 4577
Novel 16024 (44%) 6189 8921 (43%) 4691
Total
a 35721 7968 20898 6697
Estimations
Conserved currently novel 6997 5206
Total conserved
b 14729 14729
aFrom a total of 10818 genes examined.
bTotal conserved ¼ 2526 (already identified) + 6997 (estimated conserved
from human ‘novels’) + 5206 (estimated conserved from mouse ‘novels’).
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transcripts. We performed the following exercise to estimate
the extent of ‘human only’ and ‘mouse only’ events. Using
genomic sequence conservation of exons based on cross-
species transcript alignment, we found that 27% of minor
cassette exons in human genes and 37% in mouse genes are
conserved in the opposing genome at >75% identity (Supple-
mentary Figure S2). This estimate of 27% conservation rate is
close to the 25% and 27% rates previously reported (11,12).
Assuming that alternative splices are conserved at a similar
level as cassette exons, we estimate that human transcripts
contain a total of 9523 conserved alternative splices (25%
of the 35721 human splices identiﬁed) and mouse transcripts
contain 7732 conserved alternative splices (27% of the 20898
mouse splices identiﬁed) (Table 1). We have identiﬁed
2526 transcript conserved alternative splices, thus mouse tran-
scripts currently contain 5206 undetected human conserved
alternative splices (7732–2526), more than doubling the num-
ber of currently identiﬁed conserved alternative splices.
Moreover, our estimate indicates at least 14729 conserved
alternative splices (9523 + 7732   2526) exist in these
10818 genes, yielding an average of 1.4 conserved events
per gene.
Expressionofconservedanddivergedalternativesplices
Using Z-score to represent the transcript coverage of a splice
relative to mutually exclusive splicing events, we saw a strong
correlation (R ¼ 0.75) for 51164 conserved splice pairs
between mouse and human (Figure 2). In addition, conserved
alternative splices exhibited greater transcript coverage than
diverged or novel alternative splices (Figure 3A). Conserved
alternative splices also exhibit weaker dependency on tran-
script coverage than diverged or novel alternative splices,
suggesting that they arise from a distinct process and, perhaps
obviously, that the total number of conserved alternative
splices is limited (Figure 3B). The observation that the
level of diverged alternative splicing continues to increase
without reaching saturation even at high coverage indicates
that diverged alternative splices may be generated by a stoch-
astic process at a rate proportional to gene expression.
Furthermore, the observed lower expression of diverged
splices is consistent with the hypothesis that diverged altern-
ative splices arefrequently aberrantsplice forms generated ata
low background rate due to somatic mutations or spliceosomal
errors (12,22). When examined in terms of expression, exon
size, exon size as a factor of three, and associated intron size
(Figures 4B, S3-5), the class of novel alternative splices shows
characteristics between diverged and conserved splices,
suggesting that it is a mixture of the two. Hence, we focused
on comparing conserved and diverged alternative splices in
subsequent analysis.
We classiﬁed genes into tissue-speciﬁc sets using micro-
array measured expression levels across a panel of 52 human
Figure 2. Cross-species correlation of alternative splicing expression levels.
For each conserved alternative splice, the expression Z-score in mouse and
human transcripts is plotted. Black dots and error bars show the average and
standard deviation of binned Z-scores.
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Figure 3. Transcript-based frequency analysis of alternative splices.
(A) Cumulative frequency plot for conserved and diverged alternative splices.
Frequencyofasplicedenotesthefractionofoverlappingtranscriptscontaining
thesplice.Bydefinition,thefrequencyofminoralternativesplicesrangesfrom
0 to 0.5. (B) Average numberof distinct alternative splices per gene, binned by
the log10 of gene transcript coverage. Error bars represent 1 SD.
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Figure 4. Expression and alternative splices. (A) Microarray expression of genes with alternative splices. Mean splice scores, normalized splices per gene,
for diverged, conserved, and all alternative splices of genes over-expressed in each of 52 human tissues. Tissues are ranked by their average conserved splice
scores. ‘CL:’ denotes cell lines. Novel splices plot between diverged and conserved. (B) Tissue distribution of alternative splicing across human tissues from EST
eVOClibraryannotation.TheZ-scoremeasurestheover-representationofESTscontainingalternativesplicesinaspecifictissuerelativetothebackgroundtranscript
levels.
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tissue-expressed genes, including diverged and conserved
alternative splicing, we found genes over-expressed in testis,
brain and muscle tissues show the highest levels of alternative
splicingwhereasstomachandintestinesshowthelowestlevels
(Figure 4A). However, incorporating conservation class-
iﬁcation status shows that the level of conserved alternative
splicing is most elevated in brain sub-regions and muscle,
while diverged alternative splicing is the most enriched in
testis. Examination of the tissue origin of each splice from
ESTs further shows brain (the most enriched in conserved
alternative splices) and testis (the most enriched in diverged
alternative splices) (Figure 4B).
Integrated expression and function profiles of
alternative splices
For each GO Biological Process and tissue, we intersected the
associated GO gene set with the tissue over-expressed genes.
From this list of genes, we calculated the t-score representing
the enrichment ofalternative splices.Very different patterns of
distribution are observed for conserved and diverged altern-
ative splices (Figure 5). The most signiﬁcant enrichment of
conserved alternative splicing is found in brain-expressed
genes involved in functional processes, such as signal trans-
duction, protein modiﬁcation and ion transport (Figure 5A).
Diverged alternative splicing is enriched in genes over-
expressed in testis as well as cancerous cell lines and involved
in processes, such as protein biosynthesis, cellular responses to
stress and DNA damages (Figure 5B). Enrichment is also
observed in processes, such as protein modiﬁcation, cell
death and cell cycles that are expressed in brain tissues.
DISCUSSION
We found that the expression levels of conserved splices are
strongly correlated in mouse and human genes, suggesting that
the ‘major’ versus ‘minor’ roles of conserved splice forms
were largely established before the divergence of human
and rodents and were maintained to the present. Furthermore,
as the relative expression levels of these splice forms are
similar, the splicing regulatory mechanisms appear conserved
between human and mouse. These results complement recent
ﬁndings of similar splicing regulatory sequences and factors in
mouse and human (26).
Species-speciﬁc alternative splicing events are not neces-
sarily void of function; however, evolutionary conservation at
the sequence level is an established indicator of functional
importance. Although the functional roles of individual events
needtobeexperimentallyinvestigatedonacase-by-casebasis,
strong evidence exists that non-conserved alternative splicing
events are less likely to generate functional proteins than con-
served ones (11–14). For example, non-conserved minor cas-
sette exons are more likely to cause frame-shifts than
conserved ones (95 versus 23%) (12). Alternative splicing
events that introduce frame-shifts tend to not yield a functional
protein product since the resulting mRNA is likely to be
degraded by non-sense mediated decay (27). Thus we suggest
conservation status as one proxy for the functional status of
alternative splices.
The observed distinctions between conserved and diverged
alternative splices in terms of relative abundance, functional
process and tissue expression indeed suggest a funda-
mental functional difference between these classes. Previous
studies have reported that brain and testis exhibit high levels
of alternative splicing (28,29), and microarray studies using
exon–exon junction probes revealed higher amounts of
alternative splicing in cell lines (7). However, when viewed
in terms of conservation, our results markedly demonstrate
that the greatest amount of conserved alternative splicing
occurs in the central nervous system while the high level
of alternative splicing observed in testis and cell lines is
largely diverged. Indeed, a recent study predicting conserved
exon skipping events also mentioned enrichment in brain
samples (14).
Alternative splicing in human and mouse brain may play
important roles in enriching the functional diversity of
signaling systems. Complexity generated by alternative
splicing may confer an advantage in signaling pathways
where functional capacity is enhanced by diverse ligand–
receptor interactions, similar to expanding a complex
communication network through adding nodes and con-
nections. In cancerous cell lines and testis, the prevalence
of diverged splicing may result from either more splicing
errors or faulty surveillance mechanisms. For example, the
increased levels of diverged splicing in these proliferating
cells could be the product of stressed splicing machineries
rapidly carrying out RNA splicing and protein synthesis,
or result from accumulated somatic mutations that disrupt
splicing regulation. Furthermore, in cancerous tumor or
immortalized cell lines, positive selection for aberrant splic-
ing events that disrupt regulation and promote proliferation
may occur, similar to evolutionarily selected advantageous
mutations.
In conclusion, we applied novel analysis techniques to
10818 human and mouse genes, the most comprehensive
gene set assembled to date in functional investigation of
alternative splicing, and identiﬁed important expressional
and functional distinctions between evolutionarily conserved
and diverged alternative splicing events. Conserved altern-
ative splicing is more highly expressed and less depend-
ent on transcript coverage than diverged alternative
splicing, indicating a difference in the biological processes
from which these two classes of events originate. Strong
correlation between alternative splicing expression levels in
human and mouse suggests conservation of the regulatory
mechanisms and functional roles for conserved alternative
splicing events. Furthermore, conserved alternative splicing
is more enriched in genes expressed in neuronal tissues and
signaling pathways, perhaps allowing for more complexity
and diversity. On the other hand, diverged alternative splicing
is enriched in genes expressed in testis and cancerous cell lines
where increased rate of aberrant splicing may result from
abnormal cellular conditions, rapid cell proliferation or faulty
surveillance mechanisms. Finally, computational prediction
and experimental validation of novel alternative splicing
events in human genes based on mouse transcripts suggest
that the extent of conserved alternative splicing, hence the
functional impact of alternative splicing, is far from fully
revealed.
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Figure 5. Integrated profiles across expression and GO categories. (A) T-scores measuring the enrichment of conserved alternative splices across functional and
expressionalcategories.Rowscorrespondto24functionalcategories(GO-biologicalprocess,slim)andcolumnscorrespondtogenesetsidentifiedasover-expressed
in each of 52 human tissues. Tissue-defined and GO-defined gene sets with no intersecting genes are shaded gray. (B) T-scores for diverged alternative splices.
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